MAP microba life sciences limited

Ok in relation to the testing business only, Q3 F25 growth of...

  1. 327 Posts.
    lightbulb Created with Sketch. 72
    Ok in relation to the testing business only, Q3 F25 growth of ~3% on Q3 F24. Q4 F25 growth of 4.8% on Q4 F25. The issue is the total dollar growth is $280k. That is just not going to plug the excessive cash burn. Hope they can provide us some insights at the next investor webinar, because its looking like potentially sitting and waiting for the next capital raise to then pick up cheaper stock to help average down, then potentially see some improved returns.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.4¢
Change
-0.002(2.08%)
Mkt cap ! $47.89M
Open High Low Value Volume
9.6¢ 9.6¢ 9.3¢ $8.406K 90.20K

Buyers (Bids)

No. Vol. Price($)
1 1418 9.3¢
 

Sellers (Offers)

Price($) Vol. No.
9.4¢ 32387 1
View Market Depth
Last trade - 11.16am 29/07/2025 (20 minute delay) ?
MAP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.